KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Capital Leases (2023 - 2025)

Castle Biosciences (CSTL) has disclosed Capital Leases for 3 consecutive years, with $314000.0 as the latest value for Q4 2025.

  • Quarterly Capital Leases rose 0.96% to $314000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $314000.0 through Dec 2025, up 0.96% year-over-year, with the annual reading at $314000.0 for FY2025, 0.96% up from the prior year.
  • Capital Leases hit $314000.0 in Q4 2025 for Castle Biosciences, down from $339000.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $364000.0 in Q2 2025 to a low of $25000.0 in Q4 2023.
  • Historically, Capital Leases has averaged $285250.0 across 3 years, with a median of $313000.0 in 2024.
  • Biggest five-year swings in Capital Leases: surged 1144.0% in 2024 and later rose 0.96% in 2025.
  • Year by year, Capital Leases stood at $25000.0 in 2023, then soared by 1144.0% to $311000.0 in 2024, then rose by 0.96% to $314000.0 in 2025.
  • Business Quant data shows Capital Leases for CSTL at $314000.0 in Q4 2025, $339000.0 in Q3 2025, and $364000.0 in Q2 2025.